Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Allarity Therapeutics, Inc.

Core Viewpoint - A class action lawsuit has been filed against Allarity Therapeutics, Inc. for allegedly misleading investors regarding the regulatory prospects of its Dovitinib NDA, with claims of improper conduct and increased risk of scrutiny [1]. Group 1: Allegations Against Allarity Therapeutics - The lawsuit alleges that Allarity overstated the regulatory prospects of the Dovitinib NDA [1]. - It is claimed that Allarity and three former officers engaged in illegal or improper conduct related to the Dovitinib NDA and Dovitinib-DRP PMA [1]. - The misconduct reportedly increased the risk of regulatory scrutiny and potential enforcement actions, leading to significant legal and reputational harm [1]. - Following the announcement of an investigation into wrongdoing, Allarity allegedly downplayed the likelihood of enforcement actions resulting from the investigation [1]. - As a result, the company's public statements were deemed materially false and misleading throughout the class period [1]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their applications by November 12, 2024 [2]. - Participation in the case is not required to be eligible for recovery; shareholders can remain absent class members if they choose [2]. Group 3: About Robbins LLP - Robbins LLP is a recognized leader in shareholder rights litigation, having recovered over $1 billion for shareholders since its inception in 2002 [3]. - The firm operates on a contingency fee basis, meaning shareholders pay no fees or expenses unless they recover losses [3].